Citations

Clear

31 citation(s) found for "Ivy, Percy".

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Barry, William T., Wenham, Robert M. , Hendrickson, Andrea E. Wahner , Armstrong, Deborah K. , Chan, Nancy , Lee, Jung‐Min , Penson, Richard T. , Cristea, Mihaela , Abbruzzese, James L. , Matsuo, Koji , Olawaiye, Alexander , Farooq, Sarah , Kohn, Elise C. , Matulonis, Ursula A. , Liu, Joyce F. , Cohn, David E. , Swisher, Elizabeth M. , Van Allen, Eliezer M , Shapiro, Geoffrey I. , Ivy, S. Percy

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5519-5519

10.1200/jco.2018.36.15_suppl.5519 Get It

A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer
Erlichman, Charles , Toft, D O, Reid, J., Ames, M. M., Mandrekar, Sumithra J. , Ajei, A., McCollum, Andrea K., Ivy, Percy, Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | April 5, 2017 | Volume: 22 | Issue: 14_suppl | Pages: 3030-3030

10.1200/jco.2004.22.90140.3030 Get It

The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects
Mansfield, Aaron S. , Vulih, Diana, Harris, Pamela Jo , Rudek, Michelle A. , Smith, Gary L. N. , Ivy, S. Percy , Mansfield, Aaron S

Mayo Clinic

Clinical Cancer Research | May 17, 2016 | Volume: 22 | Issue: 22 | Pages: 5472-5479

10.1158/1078-0432.ccr-16-0449 | PMID 27189163 Get It

Abstract Purpose: The NCI Cancer Therapy Evaluation Program sponsors hepatic dysfunction phase I clinical trials (HDCT) and phase 1 clinical trials (P1CT) to determine safe doses and schedules of antineoplastic therapeutics. We sought to compare clinical outcomes between these trial types while stratifying by hepatotoxic agents. Experimental Design: Individual subject data were extracted from the records of 51 NCI-sponsored HDCT and P1CT. The NCI's Organ Dysfunction Working Group's hepatic impairment categorization and two drug-induced liver injury (DILI) scales (FDA R ratio and Hy's law) were used to classify subjects. The number of cycles administered and treatment discontinuation reason were also evaluated and compared between groups. Results: There were 513 and 1,328 subjects treated on HDCT (n = 9) and P1CT (n = 42), respectively. There were differing patterns of DILI with significant worsening of total bilirubin in subjects on HDCT, and worsening of alanine aminotransferase (ALT) in subjects on P1CT. Cholestatic peak patterns of liver impairment (predominant increases in alkaline phosphatase rather than transaminases) were more frequent in HDCT. Criteria for Hy's law were met by 11 subjects on P1CT, but not by any subjects on HDCT. Disease progression was the most common reason for treatment discontinuation, followed by adverse events at similar frequencies in both HDCT and P1CT. Conclusions: The differential effects on hepatotoxicity suggest that underlying hepatic function may affect susceptibility to and patterns of DILI. The incorporation of additional measures of hepatic function may help identify those at highest risk of hepatotoxicity in future trials because baseline liver tests did not. Clin Cancer Res; 22(22); 5472–9. ©2016 AACR.
Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
Bradbury, Penelope A., LoRusso, Patricia , Baker, Laurence H. , Rubinstein, Larry , Huang, Erich , Groshen, Susan , Reeves, Steven A., Ellis, Lee M. , Rosner, Gary L. , Ratain, Mark J. , Paller, Channing J. , Ivy, S. Percy , Seymour, Lesley , Collyar, Deborah , Sargent, Daniel J. , LeBlanc, Michael , Rubinstein, Larry V

Mayo Clinic

Clinical Cancer Research | August 14, 2014 | Volume: 20 | Issue: 16 | Pages: 4210-4217

10.1158/1078-0432.ccr-14-0521 | PMID 25125258 Get It

Abstract Anticancer drugs are combined in an effort to treat a heterogeneous tumor or to maximize the pharmacodynamic effect. The development of combination regimens, while desirable, poses unique challenges. These include the selection of agents for combination therapy that may lead to improved efficacy while maintaining acceptable toxicity, the design of clinical trials that provide informative results for individual agents and combinations, and logistic and regulatory challenges. The phase I trial is often the initial step in the clinical evaluation of a combination regimen. In view of the importance of combination regimens and the challenges associated with developing them, the Clinical Trial Design (CTD) Task Force of the National Cancer Institute Investigational Drug Steering Committee developed a set of recommendations for the phase I development of a combination regimen. The first two recommendations focus on the scientific rationale and development plans for the combination regimen; subsequent recommendations encompass clinical design aspects. The CTD Task Force recommends that selection of the proposed regimens be based on a biologic or pharmacologic rationale supported by clinical and/or robust and validated preclinical evidence, and accompanied by a plan for subsequent development of the combination. The design of the phase I clinical trial should take into consideration the potential pharmacokinetic and pharmacodynamic interactions as well as overlapping toxicity. Depending on the specific hypothesized interaction, the primary endpoint may be dose optimization, pharmacokinetics, and/or pharmacodynamics (i.e., biomarker). Clin Cancer Res; 20(16); 4210–7. ©2014 AACR.
Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single-Arm Phase II Trials
Chansky, Kari, Rubinstein, Larry , Catalano, Paul J. , Crowley, John, Philip, Philip A. , LeBlanc, Michael , Seymour, Lesley , Ivy, S. Percy , Alberts, Steven R. , Rubinstein, Larry V

Mayo Clinic

Clinical Cancer Research | June 10, 2014 | Volume: 20 | Issue: 16 | Pages: 4176-4185

10.1158/1078-0432.ccr-13-2024 | PMID 24914040 Get It

AbstractWe compiled and analyzed a database of cooperative group trials in advanced pancreatic cancer to develop historical benchmarks for overall survival (OS) and progression-free survival (PFS). Such benchmarks are essential for evaluating new therapies in a single-arm setting. The analysis included patients with untreated metastatic pancreatic cancer receiving regimens that included gemcitabine, between 1995 and 2005. Prognostic baseline factors were selected by their significance in Cox regression analysis. Outlier trial arms were identified by comparing individual 6-month OS and PFS rates against the entire group. The dataset selected for the generation of OS and PFS benchmarks was then tested for intertrial arm variability using a logistic-normal model with the selected baseline prognostic factors as fixed effects and the individual trial arm as a random effect. A total of 1,132 cases from eight trials qualified. Performance status and sex were independently significant for OS, and performance status was prognostic for PFS. Outcomes for one trial (NCCTG-034A) were significantly different from the other trial arms. When this trial was excluded, the remaining trial arms were homogeneous for OS and PFS outcomes after adjusting for performance status and sex. Benchmark values for 6-month OS and PFS are reported along with a method for using these values in future study design and analysis. The benchmark survival values were generated from a dataset that was homogeneous between trials. The benchmarks can be used to enable single-arm phase II trials using a gemcitabine platform, especially under certain circumstances. Such circumstances might be when a randomized control arm is not practically feasible, an early signal of activity of an experimental agent is being explored such as in expansion cohorts of phase I studies, and in patients who are not candidates for combination cytotoxic therapy. Clin Cancer Res; 20(16); 4176–85. ©2014 AACR.
Profound Hair and Skin Hypopigmentation in an African American Woman Treated With the Multi-Targeted Tyrosine Kinase Inhibitor Pazopanib
Sideras, Kostandinos , Menefee, Michael E., Burton, Jill K., Erlichman, Charles , Bible, Keith C. , Ivy, S. Percy , Sideras, Kostandinos

Mayo Clinic

Journal of Clinical Oncology | June 2, 2010 | Volume: 28 | Issue: 19 | Pages: e312-e313

10.1200/jco.2009.26.4432 | PMID 20516434 Get It

The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Sargent, Daniel J. , Spriggs, David R. , Baker, Laurence, Rubinstein, Larry , Ratain, Mark J. , Blanc, M , Stewart, David B. , Crowley, John, Groshen, Susan , Humphrey, Jeffrey S., West, Pamela , Berry, Donald A. , Seymour, Lesley , Ivy, S. Percy , Sargent, Daniel J , Rubinstein, Larry V

Mayo Clinic

Clinical Cancer Research | March 10, 2010 | Volume: 16 | Issue: 6 | Pages: 1764-1769

10.1158/1078-0432.ccr-09-3287 | PMID 20215557 Get It

Abstract The optimal design of phase II studies continues to be the subject of vigorous debate, especially studies of newer molecularly targeted agents. The observations that many new therapeutics “fail” in definitive phase III studies, coupled with the numbers of new agents to be tested as well as the increasing costs and complexity of clinical trials, further emphasize the critical importance of robust and efficient phase II design. The Clinical Trial Design Task Force (CTD-TF) of the National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) has published a series of discussion papers on phase II trial design in Clinical Cancer Research. The IDSC has developed formal recommendations about aspects of phase II trial design that are the subject of frequent debate, such as endpoints (response versus progression-free survival), randomization (single-arm designs versus randomization), inclusion of biomarkers, biomarker-based patient enrichment strategies, and statistical design (e.g., two-stage designs versus multiple-group adaptive designs). Although these recommendations in general encourage the use of progression-free survival as the primary endpoint, randomization, inclusion of biomarkers, and incorporation of newer designs, we acknowledge that objective response as an endpoint and single-arm designs remain relevant in certain situations. The design of any clinical trial should always be carefully evaluated and justified based on characteristic specific to the situation. Clin Cancer Res; 16(6); 1764–9
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors
Ramanathan, Ramesh K., Egorin, Merrill J., Erlichman, Charles , Remick, Scot C. , Naret, C, Holleran, Julianne L. , TenEyck, Cynthia J., Belani, Chandra P. , Ramalingam, Suresh S. , Ivy, S. Percy

Mayo Clinic

Journal of Clinical Oncology | February 23, 2010 | Volume: 28 | Issue: 9 | Pages: 1520-1526

10.1200/jco.2009.25.0415 | PMID 20177028 Get It

Purpose To define the maximum tolerated dose, toxicities, pharmacokinetics, and pharmacodynamics of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG). Methods 17DMAG was given intravenously over 1 hour daily for 5 days (schedule A) or daily for 3 days (schedule B) every 3 weeks. Plasma 17DMAG concentrations were measured by liquid chromatography/mass spectrometry. Heat-shock proteins (HSPs) and client proteins were evaluated at baseline and after treatment on day 1 in peripheral blood mononuclear cells (PBMCs) and in pre- and post-treatment (24 hours) biopsies done during cycle 1 at the recommended phase II dose (n = 7). Results Fifty-six patients were entered: 26 on schedule A; 30 on schedule B. The recommended phase II doses for schedules A and B were 16 mg/m2 and 25 mg/m2, respectively. Grade 3/4 toxicities included liver function test elevation (14%), pneumonitis (9%), diarrhea (4%), nausea (4%), fatigue (4%) and thrombocytopenia (4%). There were no objective responses. Four patients had stable disease. 17DMAG half-life was 24 ± 15 hours. 17DMAG area under the curve (range, 0.7 to 14.7 mg/mL × h) increased linearly with dose. The median HSP90, HSP70, and integrin-linked kinase levels were 87.5% (n = 14), 124% (n = 20), and 99.5% (n = 20) of baseline. Changes in HSPs and client proteins in tumor biopsies were not consistent between baseline and 24 hours nor did they change in the same direction as those in PBMCs collected at the time of biopsy. Conclusion The recommended phase II doses of 17DMAG (16 mg/m2 × 5 days or 25 mg/m2 × 3 days, every 3 weeks) are well tolerated and suitable for further evaluation.
Randomized Phase II Designs
Rubinstein, Larry , Ivy, Percy, Sargent, Daniel J. , Crowley, John W , LeBlanc, Michael , Sargent, Daniel J , Rubinstein, Larry V

Mayo Clinic

Clinical Cancer Research | March 11, 2009 | Volume: 15 | Issue: 6 | Pages: 1883-1890

10.1158/1078-0432.ccr-08-2031 | PMID 19276275 Get It

Abstract As the use of molecularly targeted agents, which are anticipated to increase overall survival (OS)and progression-free survival (PFS) but not necessarily tumor response, has increased in oncology, there has been a corresponding increase in the recommendation and use of randomized phase II designs. Such designs reduce the potential for bias, existent in comparisons with historical controls, but also substantially increase the sample size requirements. We review the principal statistical designs for historically controlled and randomized phase II trials, along with their advantages, disadvantages, and statistical design considerations. We review the arguments for and against the use of randomization in phase II studies, the situations in which the use of historical controls is preferred, and the situations in which the use of randomized designs is preferred. We review methods used to calculate predicted OS or PFS values from historical controls, adjusted so as to be appropriate for an experimental sample with particular prognostic characteristics. We show how adjustment of the type I and type II error bounds for randomized studies can facilitate the detection of appropriate target increases in median PFS or OS with sample sizes appropriate for phase II studies. Although there continue to be differences among investigators concerning the use of randomization versus historical controls in phase II trials, there is agreement that each approach will continue to be appropriate, and the optimal approach will depend upon the circumstances of the individual trial.
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
Heath, Elisabeth I. , Vaishampayan, Ulka N. , Sheng, Shijie , Sarkar, Fazlul H., Harper, Felicity W. K. , Gaskins, Melvin, Pitot, Henry C., Tan, Winston , Пили, Роберто , Erlichman, Charles , Liu, Glenn , Hillman, David W. , Ivy, S. Percy , Carducci, Michael A. , Vaishampayan, Ulka

Mayo Clinic

Clinical Cancer Research | December 1, 2008 | Volume: 14 | Issue: 23 | Pages: 7940-7946

10.1158/1078-0432.ccr-08-0221 | PMID 19047126 Get It

Abstract Purpose: 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is a benzoquinone ansamycin antibiotic with antiproliferative activity in several mouse xenograft models, including prostate cancer models. A two-stage phase II study was conducted to assess the activity and toxicity profile of 17-AAG administered to patients with metastatic, hormone-refractory prostate cancer. Experimental Design: Patients with at least one prior systemic therapy and a rising prostate-specific antigen (PSA) were eligible. Patients received 17-AAG at a dose of 300 mg/m2 i.v. weekly for 3 of 4 weeks. The primary objective was to assess the PSA response. Secondary objectives were to determine overall survival, to assess toxicity, and to measure interleukin-6, interleukin-8, and maspin levels and quality of life. Results: Fifteen eligible patients were enrolled. The median age was 68 years and the median PSA was 261 ng/mL. Patients received 17-AAG for a median number of two cycles. Severe adverse events included grade 3 fatigue (four patients), grade 3 lymphopenia (two patients), and grade 3 back pain (two patients). The median PSA progression-free survival was 1.8 months (95% confidence interval, 1.3-3.4 months). The 6-month overall survival was 71% (95% confidence interval, 52-100%). Conclusions: 17-AAG did not show any activity with regard to PSA response. Due to insufficient PSA response, enrollment was stopped at the end of first stage per study design. The most significant severe toxicity was grade 3 fatigue. Further evaluation of 17-AAG at a dose of 300 mg/m2 i.v. weekly as a single agent in patients with metastatic, hormone-refractory prostate cancer who received at least one prior systemic therapy is not warranted.